Phreesia (PHR) – Research Analysts’ Weekly Ratings Changes

Phreesia (NYSE: PHR) recently received a number of ratings updates from brokerages and research firms:

• 12/16/2025 – Phreesia had its price target lowered by analysts at Barclays PLC from $26.00 to $24.00. They now have an “overweight” rating on the stock.
• 12/10/2025 – Phreesia was given a new $29.00 price target on by analysts at Truist Financial Corporation.
• 12/10/2025 – Phreesia had its price target lowered by analysts at Mizuho from $36.00 to $28.00. They now have an “outperform” rating on the stock.
• 12/10/2025 – Phreesia had its price target lowered by analysts at Robert W. Baird from $31.00 to $25.00. They now have an “outperform” rating on the stock.
• 12/9/2025 – Phreesia had its price target lowered by analysts at Canaccord Genuity Group Inc. from $38.00 to $33.00. They now have a “buy” rating on the stock.
• 12/9/2025 – Phreesia had its price target lowered by analysts at Citigroup Inc. from $34.00 to $29.00. They now have a “buy” rating on the stock.
• 12/9/2025 – Phreesia had its price target lowered by analysts at JPMorgan Chase & Co. from $32.00 to $29.00. They now have an “overweight” rating on the stock.
• 12/8/2025 – Phreesia is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $26.00 price target on the stock.
• 12/8/2025 – Phreesia was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 12/8/2025 – Phreesia is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $26.00 price target on the stock.
• 12/8/2025 – Phreesia had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock.
• 12/2/2025 – Phreesia had its price target raised by analysts at DA Davidson from $33.00 to $35.00. They now have a “buy” rating on the stock.
• 11/13/2025 – Phreesia is now covered by analysts at BMO Capital Markets. They set an “outperform” rating and a $32.00 price target on the stock.

Insiders Place Their Bets

In other news, insider David Linetsky sold 2,059 shares of Phreesia stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $22.36, for a total transaction of $46,039.24. Following the completion of the transaction, the insider directly owned 171,829 shares in the company, valued at approximately $3,842,096.44. The trade was a 1.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel Allison C. Hoffman sold 1,241 shares of Phreesia stock in a transaction on Friday, October 17th. The stock was sold at an average price of $22.36, for a total transaction of $27,748.76. Following the transaction, the general counsel directly owned 135,737 shares of the company’s stock, valued at approximately $3,035,079.32. This trade represents a 0.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 7,534 shares of company stock valued at $165,514. 5.50% of the stock is currently owned by corporate insiders.

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.